South Korean Cancer Center Achieves International Recognition for Advanced Ovarian Cancer Surgery
Seoul, South Korea – The National Cancer Center (NCC) of South Korea has become the first institution in the country to receive accreditation in advanced ovarian cancer surgery from the European Society of Gynaecological Oncology (ESGO). This prestigious certification, awarded on March 6, 2026, recognizes the NCC’s exceptional expertise in managing complex cases of advanced ovarian cancer and signifies a major advancement in specialized cancer care within South Korea. The accreditation is a significant milestone, validating the NCC’s commitment to providing world-class treatment and improving outcomes for patients facing this challenging disease.
The ESGO accreditation specifically focuses on the surgical management of “advanced ovarian cancer,” considered one of the most demanding areas within gynecologic oncology. It serves as an international benchmark for evaluating the specialized skills and capabilities of medical centers globally. Achieving this certification demonstrates that the NCC meets rigorous international standards in both clinical practice and surgical proficiency. The NCC will maintain this accreditation for the next five years, subject to ongoing evaluation and adherence to ESGO’s standards.
A Multidisciplinary Approach to Patient Care
The National Cancer Center’s success in obtaining this accreditation is attributed to its collaborative, multidisciplinary approach to patient care. The center’s Uterine and Ovarian Cancer Center serves as a hub, bringing together specialists from various departments to develop personalized treatment plans for each patient. This collaborative model ensures that patients benefit from a comprehensive and integrated care strategy. The NCC emphasizes data-driven improvements, utilizing information gathered from clinical practice to inform both foundational and clinical research initiatives.
Central to this success is the work of Professor Sang-Yun Park, a leading figure in ovarian cancer treatment at the NCC. Professor Park has been instrumental in pioneering advanced surgical techniques, including maximal debulking surgery and cytoreductive surgery, which have demonstrably improved survival rates and quality of life for patients. According to the National Cancer Center, Professor Park’s introduction of these techniques has significantly contributed to positive patient outcomes.
Advancements in Surgical Techniques and Research
Professor Park’s contributions extend beyond surgical innovation. He has also led research demonstrating the safety and efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer, a specialized treatment involving the delivery of chemotherapy directly into the abdominal cavity. This research has helped to establish HIPEC as a viable treatment option for select patients. Professor Park played a key role in drafting the 2006 Korean guidelines for gynecologic cancer treatment and has been a driving force in research aimed at understanding the genetic basis of ovarian cancer, contributing to advancements in diagnostic capabilities. His dedication to the field was recognized in 2019 with the Dongbaek Medal, a national honor.
The ESGO accreditation process involves a thorough evaluation of a center’s surgical volume, complexity of cases, surgical techniques, and overall patient outcomes. The NCC’s ability to meet these stringent criteria underscores its commitment to providing the highest quality of care. As reported by Medipana News, the certification is a testament to the NCC’s dedication to advancing the field of gynecologic oncology.
Impact on Ovarian Cancer Treatment in South Korea
Ovarian cancer is a particularly challenging disease, often diagnosed at a late stage, which can significantly impact treatment options and outcomes. The ESGO accreditation positions the National Cancer Center as a leading center for advanced ovarian cancer care in South Korea, offering patients access to cutting-edge treatments and specialized expertise. This achievement is expected to attract patients from across the country and potentially from abroad, seeking the highest standard of care.
The certification also serves as a catalyst for further advancements in ovarian cancer research and treatment within South Korea. The NCC’s success is likely to inspire other institutions to strive for similar levels of excellence, ultimately benefiting patients nationwide. The center’s commitment to multidisciplinary collaboration and data-driven research will continue to drive innovation in the field.
Looking Ahead: Continued Commitment to Excellence
The National Cancer Center’s attainment of ESGO accreditation marks a pivotal moment in the fight against ovarian cancer in South Korea. The center remains dedicated to maintaining its high standards of care and continuing to push the boundaries of research and innovation. With a focus on personalized treatment, collaborative care, and a commitment to improving patient outcomes, the NCC is poised to remain at the forefront of gynecologic oncology for years to come.
The NCC will continue to focus on expanding its research initiatives, refining its surgical techniques, and fostering collaboration with other leading institutions around the world. The center’s ultimate goal is to provide hope and improved quality of life for all patients affected by ovarian cancer. The next major update from the National Cancer Center regarding its ovarian cancer program is expected in late 2026, following a review of the first year of data post-accreditation.
What are your thoughts on this significant achievement for South Korean cancer care? Share your comments below, and please share this article with your network to raise awareness about advancements in ovarian cancer treatment.